TGFB1 and colitis: Consistently, genetically modified mice, which bear a dominant-negative TβR2 and are unresponsive to TGF-β1, as well as mice with T-cell targeted deletion of TβR2, develop systemic autoimmunity ultimately resulting in a severe colitis [16].